![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://figures.semanticscholar.org/d83a64f6b7193358c31030487761fc19c80dd33c/3-Figure1-1.png)
glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of
Description
I 2 = 0%), and 30-day mortality rate ( OR 0.54
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://www.frontiersin.org/files/Articles/1462240/xml-images/fneur-15-1462240-g001.webp)
For the efficacy estimand, the LSM change in HbA1c from baseline at week 52 as the primary endpoint was 2.24%, 2.43%, and 2.58% with tirzepatide 5, 10, and 15 mg, respectively, versus 1.44% with insulin glargine
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-018-0593-6/MediaObjects/40263_2018_593_Fig1_HTML.png)
& Brubaker, P
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40290-020-00374-5/MediaObjects/40290_2020_374_Fig1_HTML.png)
The patients who received 5 mg were found to have 0.70% in HbA1c level versus 0.72% in the group that received 15 mg [25]
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12929-024-01090-x/MediaObjects/12929_2024_1090_Fig1_HTML.png)
Week 5 reassessment: Check inflammatory markers (CRP, ESR, relevant condition-specific markers)
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1336005755226597)
Guideline source: BMJ/MAGIC Group Evidence rating system used
![glp 1 agonist parkinson PDF] Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models Frontiers | Neuroprotective effects of](https://scienceofparkinsons.com/wp-content/uploads/2017/08/bydureon_pen_image.jpg)
